In the United States, over 2 million individuals openly identify with a gender that differs from their sex assigned at birth. A cancer diagnosis is physically and psychologically taxing—and, in some, traumatic. However, for transgender and gender-diverse (TGD) people, many of whom have experienced discrimination in myriad health care settings, the challenges may be even greater. These recommendations focus on how best to deliver quality cancer care to transgender men (individuals who identify as men but were assigned female sex at birth), transgender women (individuals who identify as women but were assigned male sex at birth), and people who identify somewhere beyond this gender spectrum as nonbinary or using other terms, based on the available, albeit sparse, literature. This review broaches: (1) the epidemiology of cancer in TGD individuals, including the incidence of cancer and cancer-related mortality; (2) cancer center practices that are welcoming and affirming to TGD patients; (3) the need for awareness and intentionality in the spaces of diagnosis and treatment for cancer; (4) the inevitable conclusion that gender differences exist but much more needs to be learned about the impact of gender-affirming therapy, consisting of gender-affirming surgeries and gender-affirming hormone therapy, on cancer therapy; and (5) the efficacy and perceived safety of antineoplastic therapy and gender-affirming hormone therapy.

中文翻译：

---

跨性别者和性别多元化人群的癌症护理：来自癌症支持性护理多国协会的实用、文献驱动的建议


在美国，超过 200 万人公开认同的性别与他们出生时被分配的性别不同。癌症诊断在身体和心理上都很费力，而且在某些情况下，还会带来创伤。然而，对于跨性别者和性别多元化 （TGD） 人来说，他们中的许多人在无数的医疗保健环境中经历过歧视，挑战可能更大。这些建议的重点是如何最好地为跨性别男性（认同为男性但在出生时被分配为女性的个体）、跨性别女性（认同为女性但在出生时被分配为男性的个体）以及认同超出此性别范围的某个地方为非二元性别或使用其他术语的人提供优质的癌症护理，根据可用的、 尽管稀疏，文学。本综述提出：（1） TGD 个体癌症的流行病学，包括癌症发病率和癌症相关死亡率;（2） 欢迎和肯定 TGD 患者的癌症中心实践;（3） 在癌症诊断和治疗领域需要有意识和有意识;（4） 不可避免的结论是性别差异存在，但需要更多地了解性别肯定疗法（包括性别肯定手术和性别肯定激素疗法）对癌症治疗的影响;（5） 抗肿瘤治疗和性别肯定激素治疗的疗效和感知安全性。